{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T13:26:29Z","timestamp":1769952389870,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.kint.2021.12.003","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:04:45Z","timestamp":1642565085000},"page":"224-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["BLISS-LN trial revisited: function matters"],"prefix":"10.1016","volume":"101","author":[{"given":"Sarah","family":"Gleeson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Lightstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.12.003_bib1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.12.003_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.kint.2021.12.003_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A\u00a0secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.12.003_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.13101019","article-title":"Identifying outcomes important to patients with glomerular disease and their caregivers","volume":"15","author":"Carter","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.12.003_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A\u00a0proteinuria cut-off level of 0.7g\/day after 12\u00a0months of treatment best predicts long-term renal outcome in lupus nephritis:data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.kint.2021.12.003_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.ajkd.2014.02.020","article-title":"Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.12.003_bib7","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.12.003_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2021.12.003_bib9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ekir.2020.05.011","article-title":"Creatinine fluctuation in patients with lupus\u00a0nephritis: considerations for clinical trial endpoints","volume":"5","author":"Almaani","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2021.12.003_bib10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.12.003_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.1016\/j.kint.2022.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000}}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821011455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821011455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:54:43Z","timestamp":1769907283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821011455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0085253821011455"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.12.003","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BLISS-LN trial revisited: function matters","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.07.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.08.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}